MET and pancreatic adenocarcinoma: Hence, it can be speculated that MET is a candidate therapeutic target in pancreatic adenocarcinoma and highlighted a collaborative combination of drugs warranting clinical evaluation for pancreatic adenocarcinoma treatment.